Zimmer Biomet stock gains after dividend update and steady valuation

Published on 09/19/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zimmer Biomet stock closed at USD 95.36 on September 18, 2026 on the NYSE after announcing a USD 0.24 cash dividend with an ex-dividend date of September 30, 2026. The shares reflect a market capitalization of about USD 18.0 billion as of mid September 2026.

Titan-Knieimplantat auf Edelstahltisch in steriler Medizintechnik-Fertigung — Zimmer Biomet US98956P1021 zeigt Titan-Knieimplantat mit orthopädischen Instrumenten in steriler Fertigungsumgebung nahaufnahme, Illustration mit AI erstellt.

Zimmer Biomet stock (ISIN US98956P1021) ended the last completed trading session at USD 95.36 on the New York Stock Exchange on September 18, 2026, up 1.18 percent from the previous close of USD 94.25. The orthopedic device maker has also confirmed a cash dividend of USD 0.24 per share with an ex-dividend date set for September 30, 2026, giving investors a visible near-term income event.

Dividend and valuation signal for investors

According to Yahoo Finance, Zimmer Biomet’s forward dividend stands at USD 0.96 per share for fiscal year 2026, which translates into a forward dividend yield of 1.02 percent as of September 18, 2026 based on the closing price of USD 95.36. This implies that the annualized dividend has been set at roughly four times the announced quarterly distribution of USD 0.24, underscoring management’s intent to maintain a consistent payout profile.

The same data show a 52-week trading range for Zimmer Biomet stock between USD 79.12 and USD 106.88, with the September 18, 2026 closing price sitting about 20.5 percent above the 52-week low and around 10.8 percent below the 52-week high. These levels indicate that the shares are trading in the upper half of their one-year band but still below recent peaks, a profile that often reflects improved sentiment without fully pricing in a best-case scenario.

Market capitalization and peer context

Zimmer Biomet’s equity valuation is also supported by its market capitalization metrics. As of mid September 2026, the company’s market cap is reported at USD 17.97 billion, placing it among the world’s roughly 1,300 most valuable listed companies by market value, according to CompaniesMarketCap. On September 17, 2026, the same source and Nasdaq data indicated a market capitalization of USD 17.98 billion, highlighting a marginal decline of about 0.06 percent over that one-day period, consistent with the small daily share-price fluctuations typical in a mature medical devices issuer.

Zimmer Biomet operates in the global medical devices sector, competing with large diversified peers in orthopedics and surgical technologies. While the latest search results do not carry fresh quarterly revenue or earnings figures within the required recency window, sector overviews show that medical devices remain a sizable and steadily expanding market. For example, a recent industry article on the medical devices market describes how established players such as Medtronic, Johnson & Johnson, Stryker, Smith+Nephew and Boston Scientific dominate the competitive landscape, underscoring the scale of the environment in which Zimmer Biomet competes, as reported by Yahoo Finance on September 18, 2026.

Stock near the middle of its 52-week range

Price data from Reuters confirm that Zimmer Biomet stock traded at USD 94.25 as of September 18, 2026, with the 52-week range likewise indicated between USD 79.12 and USD 106.88. Taken together with the USD 95.36 close on the same trading day reported by Yahoo Finance, the data suggest a relatively narrow intraday band and a stable, mid-range position compared with the one-year extremes. For investors, this combination of a modest dividend yield, mid-range valuation and a market capitalization around USD 18.0 billion provides a picture of a mature, income-paying healthcare stock rather than a high-volatility growth play.

Zimmer Biomet stock price snapshot

As of the close on September 18, 2026, Zimmer Biomet stock traded at USD 95.36 on the New York Stock Exchange, representing a 1.18 percent gain versus the prior close of USD 94.25 and leaving the shares roughly 10.8 percent below their 52-week high of USD 106.88 and 20.5 percent above the 52-week low of USD 79.12. The company’s market capitalization stood at about USD 17.97 billion in mid September 2026, with investors also eyeing the upcoming USD 0.24 per-share cash dividend and the associated September 30, 2026 ex-dividend date.